Add Formweb to your mobile device
Approved Formulary
Search results for:
donepezil-memantine
donepezil-memantine
- Restricted Medications Non-Formulary
Brand names: Namzaric
No brands, forms, or strengths have been added for this generic.
Display Parasympathomimetic (Cholinergic) Agents, Central Nervous System Agents, Miscellaneous Class:
120400, 289200
Medication comments:
| Per policy, orders for these non-formulary agents will be changed to formulary equivalents. | |
|---|---|
| Non-Formulary Agent | Formulary Equivalent |
| donepezil-memantine (Namzaric) | donepezil (Aricept) 10 mg + menantine (Namenda) as appropriate to match order |
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | donepezil (Aricept) |
| Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3) | |
| Drug(s) ⇆ disease or syndrome | cholinesterase inhibitors (AChEIs) ⇄ Syncope |
| Rationale | AChEIs cause bradycardia and should be avoided in older adults whose syncope may be due to bradycardia. |
| Recommendation | Avoid |
| Quality of evidence: High, Strength of Recommendation: Strong | |
Last updated: Sep. 24, 2025
- Therapeutic Interchange Policy donepezil (Aricept)
- Therapeutic Interchange Policy memantine (Namenda XR)